The US Food and Drug Administration named Dexcom as the first manufacturer selected for its Technology-Enabled Meaningful Patient Outcomes pilot on Tuesday. The programme, known as TEMPO, allows digital health devices to be offered to Med
I’m glad you got some feedback out of it. I think that’s where they have the most value right now. But they are too expensive and too inconsistent for the sort of mass rollout RFK wants here in the US. They need to improve a lot to move away from the style of use you got out of an OTC version.
I’m glad you got some feedback out of it. I think that’s where they have the most value right now. But they are too expensive and too inconsistent for the sort of mass rollout RFK wants here in the US. They need to improve a lot to move away from the style of use you got out of an OTC version.